P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials

N Narula,H Hamam,E C Wong,J K Marshall,V Jairath,S B Hanauer,W Reinisch,P S Dulai
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0819
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Protocols for managing steroids in clinical trials of ulcerative colitis (UC) vary. Most trials mandate steroid tapering at the beginning of maintenance phase. Adaptive steroid tapering allows for some discretion on whether to taper steroids for a patient. It remains unclear what impact steroid tapering protocols have on trial outcomes. Methods This post-hoc analysis from many clinical trials of advanced therapies in UC (VARSITY, ACT 1/2, PURSUIT, GEMINI1, OCTAVE and ULTRA2) was carried out under protocols with Vivli (00007656) and YODA (20224882). Responders to induction therapy with baseline corticosteroid use were considered as the primary population of interest. Adjustments were made to account for re-randomization designs and treatment exposure. Univariate analyses were conducted to identify baseline variables that had an association with the primary outcome of interest, one-year corticosteroid-free clinical remission (CR). All covariates with a significant univariate association (p < 0.05) were considered for inclusion in the multivariate model. Logistic regression was used to assess the impact of steroid-weaning regimen on the outcome of interest. Secondary outcome of interest was one-year CR. Results There was a total of 861 patients from the seven included trials who had achieved clinical response after induction and were using corticosteroids. Within multivariate analysis, patients using adaptive steroid weaning regimens were less likely to achieve one year corticosteroid-free CR (odds ratio (OR) 0.66 (95% CI 0.48-0.92), p=0.015). Patients with higher partial Mayo scores were also less likely to achieve one year corticosteroid-free CR (OR 0.88 (95% 0.8-0.97), p=0.012). Other variables found significant on univariate analysis were no longer significant once considered within the multivariate model (smoking, race, albumin, endoscopic Mayo score). For the secondary outcome of one year CR, patients using adaptive steroid weaning regimens had increased odds for achieving one year CR as compared to those using fixed regimens (OR 1.9 (95% 1.43-2.52), p<0.001). Several other variables were also found to have an association with one year CR within the multivariate model (Table 1). Conclusion Among patients with UC on corticosteroids at the time of study enrolment, adaptive steroid weaning regimens were less likely to achieve one-year corticosteroid-free CR but more likely to achieve one-year CR. This may help explain the findings within the VARSITY study, where patients treated with vedolizumab had increased odds for one-year CR but were less likely to achieve one-year corticosteroid-free CR. Consideration should be given to implementing mandatory steroid weaning protocols in future clinical trials of UC.
gastroenterology & hepatology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the impact of different glucocorticoid tapering regimens on corticosteroid - free clinical remission (CR) within one year in patients in ulcerative colitis (UC) clinical trials. Specifically, the study compared the effects of the adaptive steroid tapering and the forced tapering to evaluate how these different management strategies affect patients' treatment outcomes. ### Research Background In ulcerative colitis clinical trials, glucocorticoid management regimens vary. Most trials require glucocorticoid tapering at the start of the maintenance treatment phase. Adaptive glucocorticoid tapering allows doctors to decide whether to reduce the use of glucocorticoids according to the specific situation of patients. However, it is not clear how these different tapering regimens affect the results of clinical trials. ### Research Methods This post - hoc analysis integrated data from multiple clinical trials of advanced therapies for UC (such as VARSITY, ACT 1/2, PURSUIT, GEMINI1, OCTAVE and ULTRA2), and was carried out under the protocols of Vivli (00007656) and YODA (20224882). The main study population was patients who achieved a clinical response after induction therapy and were using glucocorticoids at baseline. To adjust for the effects of re - randomization design and treatment exposure, univariate analysis was performed to identify baseline variables associated with the primary outcome (corticosteroid - free clinical remission within one year). All covariates that were significant in the univariate analysis (p < 0.05) were included in the multivariate model. The impact of glucocorticoid tapering regimens on the primary outcome was evaluated by logistic regression. ### Research Results A total of 861 patients from seven included trials achieved a clinical response after induction therapy and were using glucocorticoids. Multivariate analysis showed that patients using the adaptive glucocorticoid tapering regimen were less likely to achieve corticosteroid - free clinical remission within one year (odds ratio (OR) 0.66, 95% confidence interval (CI) 0.48 - 0.92, p = 0.015). Patients with a higher partial Mayo score were also more difficult to achieve corticosteroid - free clinical remission within one year (OR 0.88, 95% CI 0.8 - 0.97, p = 0.012). For the secondary outcome (clinical remission within one year), patients using the adaptive glucocorticoid tapering regimen were more likely to achieve clinical remission within one year (OR 1.9, 95% CI 1.43 - 2.52, p < 0.001). ### Conclusion For UC patients using glucocorticoids at study enrollment, the adaptive glucocorticoid tapering regimen is less likely to achieve corticosteroid - free clinical remission within one year, but more likely to achieve clinical remission within one year. This finding helps to explain the results in the VARSITY study, that is, patients receiving vedolizumab treatment were more likely to achieve clinical remission within one year, but less likely to achieve corticosteroid - free clinical remission within one year. Future UC clinical trials should consider implementing a forced glucocorticoid tapering regimen.